| Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs AH Schinkel, JJM Smit, O van Tellingen, JH Beijnen, E Wagenaar, ... Cell 77 (4), 491-502, 1994 | 2760 | 1994 |
| Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview AH Schinkel, JW Jonker Advanced drug delivery reviews 64, 138-153, 2012 | 2102 | 2012 |
| Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease JJM Smit, AH Schinkel, RPJO Elferink, AK Groen, E Wagenaar, ... Cell 75 (3), 451-462, 1993 | 1864 | 1993 |
| P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. AH Schinkel, E Wagenaar, CA Mol, L van Deemter The Journal of clinical investigation 97 (11), 2517-2524, 1996 | 1594 | 1996 |
| Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues M Maliepaard, GL Scheffer, IF Faneyte, MA van Gastelen, ... Cancer research 61 (8), 3458-3464, 2001 | 1526 | 2001 |
| Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. AH Schinkel, E Wagenaar, LA Van Deemter, CA Mol, P Borst The Journal of clinical investigation 96 (4), 1698-1705, 1995 | 1382 | 1995 |
| P-Glycoprotein, a gatekeeper in the blood–brain barrier AH Schinkel Advanced drug delivery reviews 36 (2-3), 179-194, 1999 | 1225 | 1999 |
| Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins AH Schinkel, U Mayer, E Wagenaar, CAAM Mol, L Van Deemter, JJM Smit, ... Proceedings of the National Academy of Sciences 94 (8), 4028-4033, 1997 | 1207 | 1997 |
| Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine A Sparreboom, J Van Asperen, U Mayer, AH Schinkel, JW Smit, ... Proceedings of the National Academy of Sciences 94 (5), 2031-2035, 1997 | 1139 | 1997 |
| MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine A van Helvoort, AJ Smith, H Sprong, I Fritzsche, AH Schinkel, P Borst, ... Cell 87 (3), 507-517, 1996 | 1134 | 1996 |
| The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria JW Jonker, M Buitelaar, E Wagenaar, MA Van Der Valk, GL Scheffer, ... Proceedings of the National Academy of Sciences 99 (24), 15649-15654, 2002 | 1007 | 2002 |
| Potent and Specific Inhibition of the Breast Cancer Resistance Protein Multidrug Transporter in Vitro and in Mouse Intestine by a Novel Analogue of Fumitremorgin C JD Allen, A Van Loevezijn, JM Lakhai, M Van Der Valk, O Van Tellingen, ... Molecular cancer therapeutics 1 (6), 417-425, 2002 | 916 | 2002 |
| Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study J Fellay, C Marzolini, ER Meaden, DJ Back, T Buclin, JP Chave, ... The Lancet 359 (9300), 30-36, 2002 | 849 | 2002 |
| Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan JW Jonker, JW Smit, RF Brinkhuis, M Maliepaard, JH Beijnen, ... Journal of the National Cancer Institute 92 (20), 1651-1656, 2000 | 829 | 2000 |
| The physiological function of drug-transporting P-glycoproteins AH Schinkel Seminars in cancer biology 8 (3), 161-170, 1997 | 662 | 1997 |
| Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin DS Wang, JW Jonker, Y Kato, H Kusuhara, AH Schinkel, Y Sugiyama The Journal of pharmacology and experimental therapeutics 302 (2), 510-515, 2002 | 593 | 2002 |
| Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. R Evers, M Kool, L van Deemter, H Janssen, J Calafat, LC Oomen, ... The Journal of clinical investigation 101 (7), 1310-1319, 1998 | 578 | 1998 |
| Organic cation transporter 2 mediates cisplatin-induced oto-and nephrotoxicity and is a target for protective interventions G Ciarimboli, D Deuster, A Knief, M Sperling, M Holtkamp, B Edemir, ... The American journal of pathology 176 (3), 1169-1180, 2010 | 540 | 2010 |
| The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk JW Jonker, G Merino, S Musters, AE van Herwaarden, E Bolscher, ... Nature medicine 11 (2), 127-129, 2005 | 530 | 2005 |
| Contribution of organic cation transporter 2 (OCT2) to cisplatin‐induced nephrotoxicity KK Filipski, RH Mathijssen, TS Mikkelsen, AH Schinkel, A Sparreboom Clinical Pharmacology & Therapeutics 86 (4), 396-402, 2009 | 505 | 2009 |
